It depends on the standard you follow. As of September 2026, Tarsus Pharmaceuticals, Inc. (TARS) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 2.22% / 30% · (Cash+Inv) / Mkt Cap (36m) 9.64% / 30% · Interest income / Revenue 1.94% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 2.22% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 9.44% / 33% · Receivables / Mkt Cap (36m) 3.11% / 49% · Interest income / Revenue 1.94% / 5% | Pass |
| Dow Jones Islamic | Debt / Mkt Cap (24m) 2.22% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 9.44% / 33.33% · Receivables / Mkt Cap (24m) 3.11% / 33.33% · Interest income / Revenue 1.94% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 13.3% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 69.3% / 33.33% · Receivables / Avg Assets (4Q) 17.9% / 33.33% · Interest income / Revenue 1.94% / 5% | Fail |
| FTSE | Debt / Total Assets 14.4% / 33.33% · (Cash+ST Inv) / Total Assets 61.2% / 33.33% · (Cash+Recv) / Total Assets 81.4% / 33.33% · Interest income / Revenue 1.94% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Tarsus Pharmaceuticals, Inc. (TARS) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
Yes. Tarsus Pharmaceuticals, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.94% of each dividend: Tarsus Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is a Healthcare company (Biotechnology) with a market capitalization of $3.9B. The Maz Rating grades it against the other companies in its sector.
Tarsus Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $78.68, Tarsus Pharmaceuticals, Inc. trades at 5.7x sales and 35.1x book value. Over the last twelve months it generated about $682M of revenue and a net loss of $749M. It runs a gross margin of 93.2%, an operating margin of -102.0% and a net margin of -102.9%. It shows return on equity of -245.7%, return on invested capital of -250.0% and a free cash flow yield of 1.0%. On the balance sheet: a debt-to-equity ratio of 0.85 and a current ratio of 1.96. Over the past 52 weeks the share price ranged from $53.89 to $91.53, with a beta of 0.54.
Tarsus Pharmaceuticals, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 1 Strong Buy, 8 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.